Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Name	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Native name	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Established	1995
Type	Public health assessment body
Location	Bonn, Germany
Director	(see Organisation and Governance)
Website	(official site)

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen is an independent German assessment body based in Bonn, responsible for evaluating the clinical effectiveness and cost-effectiveness of health interventions. It operates within the framework of German health law and interacts with multiple national and international bodies to inform policy, reimbursement and clinical guidelines. The institute's work influences decisions by statutory health insurers, regulatory agencies and clinical professional societies across Europe.

History

The institute was founded in 1995 as part of health policy reforms that involved actors such as Helmut Kohl, Roman Herzog, Bundesministerium für Gesundheit, Gesetzliche Krankenversicherung, and stakeholders including Kassenärztliche Bundesvereinigung, Deutsche Krankenhausgesellschaft, Robert Koch Institute, and Paul Ehrlich Institute. Early activities paralleled the emergence of organizations like National Institute for Health and Care Excellence, Agency for Healthcare Research and Quality, Canadian Agency for Drugs and Technologies in Health, and Haute Autorité de Santé while responding to debates involving Gerhard Schröder's administration and legislative initiatives such as the SGB V. Over time the institute's remit expanded alongside developments linked to European Union directives, decisions by the Bundesverfassungsgericht, and interactions with bodies such as World Health Organization, Organisation for Economic Co-operation and Development, and academic centers like Charité – Universitätsmedizin Berlin, Universität Heidelberg, and Universität Bonn.

Organisation and Governance

Governance structures reference statutory frameworks crafted by the Bundestag and oversight from ministries including Bundesministerium für Gesundheit and coordination with institutions like Gemeinsamer Bundesausschuss, Institut für Arzneimittelentwicklung, and Paul-Ehrlich-Institut. Leadership and scientific advisory arrangements have drawn experts associated with Deutsche Forschungsgemeinschaft, Leopoldina, Stiftung Gesundheitswissen, and professors from universities such as Ludwig-Maximilians-Universität München, Universität Hamburg, and Universität zu Köln. Internal departments coordinate specialists in evidence synthesis, health economics, biostatistics and outcomes research, interacting with entities such as Robert Koch Institute, Max-Planck-Gesellschaft, Helmholtz-Gemeinschaft, and clinical networks including Deutsche Gesellschaft für Kardiologie and Deutsche Gesellschaft für Onkologie.

Mandate and Functions

The institute's statutory mandate encompasses health technology assessment, systematic reviews, and health economic evaluation that inform decisions by Gemeinsamer Bundesausschuss, Bundeszentrale für gesundheitliche Aufklärung, and statutory health insurers like AOK. It evaluates pharmaceuticals assessed by bodies such as European Medicines Agency, devices overseen by Federal Institute for Drugs and Medical Devices (BfArM), and diagnostic procedures used in settings associated with Universitätsklinikum Freiburg, Universitätsklinikum Heidelberg, and Klinikum der Friedrich-Schiller-Universität Jena. Outputs feed into guideline development by professional societies such as Deutsche Gesellschaft für Allgemeinmedizin, Deutsche Schlaganfall-Gesellschaft, and Deutsche Gesellschaft für Geriatrie and inform reimbursement frameworks tied to policies from SGB V and decisions by the Bundessozialgericht.

Methodology and Assessment Processes

Assessment methods align with international approaches employed by Cochrane Collaboration, GRADE Working Group, ISPOR, and agencies like NICE and CADTH, incorporating systematic literature searches, meta-analyses, and model-based economic evaluations. Technical processes involve collaborations with statisticians from Institut für Biometrie, health economists linked to ZEW, and clinical trialists affiliated with Deutsches Krebsforschungszentrum and Universitätsklinikum Heidelberg. The institute uses protocols comparable to standards from CONSORT, PRISMA, and guidance from European Network for Health Technology Assessment to appraise interventions ranging from pharmaceuticals evaluated under AMNOG procedures to procedures assessed in the context of DRG reimbursement.

Key Reports and Recommendations

Notable assessments have addressed pharmaceuticals and interventions involving agents approved by European Medicines Agency and debated in forums including Bundesrat and Ärztetag. Reports have covered areas such as oncology therapies discussed with Deutsche Krebsgesellschaft, cardiology interventions relevant to Deutsche Gesellschaft für Kardiologie, and screening programs intersecting with initiatives by Robert Koch Institute and Stiftung Prävention. Recommendations have informed negotiated prices involving manufacturers represented by Bundesverband der Pharmazeutischen Industrie, sparked debate with patient organizations like Deutsche Krebshilfe, and influenced guideline updates by societies such as Deutsche Diabetes Gesellschaft and Deutsche Gesellschaft für Rheumatologie.

Impact and Reception

The institute's outputs have been cited in rulings by Bundessozialgericht, policy papers from Bundesgesundheitsministerium, and coverage decisions affecting insurers including Techniker Krankenkasse and Barmer. Reception varies: professional societies such as Deutsche Gesellschaft für Innere Medizin and advocacy groups like Deutsche Herzstiftung sometimes contest conclusions, while entities including World Health Organization, OECD and academic centers such as Universität Hamburg recognize its methodological contributions. Controversies have arisen in cases similar to disputes seen around NICE guidance, involving stakeholders like pharmaceutical companies, hospital associations, and patient advocacy groups.

Collaborations and International Relations

The institute participates in networks such as European Network for Health Technology Assessment, collaborates with agencies including NICE, CADTH, IQWiG Netherlands? (comparative bodies), and engages with international organizations like World Health Organization and OECD. Academic partnerships extend to universities such as University College London, Harvard University, Karolinska Institutet, Universität Zürich, and research institutes including European Medicines Agency collaborators and institutes within the Max-Planck-Gesellschaft. It contributes to international methodological work with groups like GRADE Working Group and the Cochrane Collaboration, and participates in multicountry assessments alongside agencies such as Haute Autorité de Santé, Agenzia Italiana del Farmaco, and Agência Nacional de Vigilância Sanitária.

Category:Health technology assessment